PharmaGreen Pharmaceuticals

Belkins
PharmaGreen is a private company engaged in the pharmaceutical business through registration of its own products for marketing in the Egyptian market and the regional markets as well.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

PHARMA TECH

MODERNA HITCHES A RIDE WITH UBER TO BOOST VACCINE CONFIDENCE—AND, OF COURSE, DRIVE ACCESS

Moderna | January 15, 2021

news image

COVID-19 vaccine maker Moderna is looking for a lift from Uber—a collaboration lift, that is. The two companies say they're planning to work together to promote vaccine confidence and ease access to coronavirus shots. Early ideas include promoting vaccine safety on the Uber network and through in-app messages as well as incorporating Uber rides into the vaccination scheduling process. While those details are still in the works, the appeal of Uber as a part...

Read More

BUSINESS INSIGHTS

HIKMA AND FAES FARMA ENTER INTO EXCLUSIVE LICENSING AGREEMENT FOR THE COMMERCIALISATION OF BILASTINE TABLETS IN THE US

Hikma Pharmaceuticals PLC | September 21, 2021

news image

Hikma Pharmaceuticals PLC (Hikma), the multinational generic pharmaceutical company, announces the signing of an exclusive US license agreement with FAES Farma S.A. to commercialise Bilastine tablets, a non-sedating second generation antihistamine molecule for the treatment of allergic rhinitis and urticaria. Under the terms of the agreement, Hikma will be responsible for obtaining regulatory approval of Bilastine by the US Food and Drug Administration (FDA) and for the commercial...

Read More

PHARMA TECH

SEBELA PHARMACEUTICALS ANNOUNCES U.S. LAUNCH OF SUTAB® TABLETS, AN ALTERNATIVE TO LIQUID COLONOSCOPY PREPARATION

Sebela Pharmaceuticals | January 06, 2021

news image

Sebela Pharmaceuticals® today announced that SUTAB® (sodium sulfate, magnesium sulfate, and potassium chloride) tablets, the first tablet colonoscopy preparation to receive approval from the U.S. Food and Drug Administration (FDA) in over 10 years, is now available in the United States. SUTAB is a sulfate-based tablet colonoscopy preparation that is taken orally in a split-dose administration starting the evening before a colonoscopy. The tablets offer a safe and effective alterna...

Read More

HITGEN AND MORPHIC THERAPEUTIC EXTEND DRUG DISCOVERY RESEARCH COLLABORATION TO IDENTIFY SMALL MOLECULE LEADS AGAINST TARGETS

HitGen Inc., Morphic Therapeutic | July 06, 2020

news image

HitGen Inc. announced today that HitGen and Morphic Therapeutic have extended their drug discovery research collaboration to identify small molecule leads against targets specified by Morphic. HitGen’s industry-leading DNA-encoded library (DEL) technology platform includes over 400 billion encoded syntheses of small molecules with drug-like properties, synthesized on chemically-diverse scaffolds. The collaboration is an extension of a previous agreement which identified active lead compoun...

Read More

PHARMA TECH

Moderna | January 15, 2021

news image

MODERNA HITCHES A RIDE WITH UBER TO BOOST VACCINE CONFIDENCE—AND, OF COURSE, DRIVE ACCESS

COVID-19 vaccine maker Moderna is looking for a lift from Uber—a collaboration lift, that is. The two companies say they're planning to work together to promote vaccine confidence and ease access to coronavirus shots. Early ideas include promoting vaccine safety on the Uber network and through in-app messages as well as incorporating Uber rides into the vaccination scheduling process. While those details are still in the works, the appeal of Uber as a part...

Read More

BUSINESS INSIGHTS

Hikma Pharmaceuticals PLC | September 21, 2021

news image

HIKMA AND FAES FARMA ENTER INTO EXCLUSIVE LICENSING AGREEMENT FOR THE COMMERCIALISATION OF BILASTINE TABLETS IN THE US

Hikma Pharmaceuticals PLC (Hikma), the multinational generic pharmaceutical company, announces the signing of an exclusive US license agreement with FAES Farma S.A. to commercialise Bilastine tablets, a non-sedating second generation antihistamine molecule for the treatment of allergic rhinitis and urticaria. Under the terms of the agreement, Hikma will be responsible for obtaining regulatory approval of Bilastine by the US Food and Drug Administration (FDA) and for the commercial...

Read More

PHARMA TECH

Sebela Pharmaceuticals | January 06, 2021

news image

SEBELA PHARMACEUTICALS ANNOUNCES U.S. LAUNCH OF SUTAB® TABLETS, AN ALTERNATIVE TO LIQUID COLONOSCOPY PREPARATION

Sebela Pharmaceuticals® today announced that SUTAB® (sodium sulfate, magnesium sulfate, and potassium chloride) tablets, the first tablet colonoscopy preparation to receive approval from the U.S. Food and Drug Administration (FDA) in over 10 years, is now available in the United States. SUTAB is a sulfate-based tablet colonoscopy preparation that is taken orally in a split-dose administration starting the evening before a colonoscopy. The tablets offer a safe and effective alterna...

Read More

HitGen Inc., Morphic Therapeutic | July 06, 2020

news image

HITGEN AND MORPHIC THERAPEUTIC EXTEND DRUG DISCOVERY RESEARCH COLLABORATION TO IDENTIFY SMALL MOLECULE LEADS AGAINST TARGETS

HitGen Inc. announced today that HitGen and Morphic Therapeutic have extended their drug discovery research collaboration to identify small molecule leads against targets specified by Morphic. HitGen’s industry-leading DNA-encoded library (DEL) technology platform includes over 400 billion encoded syntheses of small molecules with drug-like properties, synthesized on chemically-diverse scaffolds. The collaboration is an extension of a previous agreement which identified active lead compoun...

Read More